Anavex Life Sciences Corp (AVXL)

[JB3729]

17-week data (12-week PART B including 5-week PART A) as well as 31-week data (26-week PART B including 5-week PART A) of all available patients demonstrate that ANAVEX 2-73 preserves average MMSE and ADCS-ADL (PART B) scores across the entire patient group.

Despite the relatively small sample size of this proof-of-concept, randomized, open-label study with oral daily doses (not optimized) of ANAVEX 2-73 ranging from 10mg to 50mg, data seems to indicate a converging and consistent response for all measurements (MMSE, ADCS-ADL, Cogstate, EEG/ERP) currently throughout 31 weeks (7 months) of ANAVEX 2-73 treatment. Patient retention rate at week 31 is 84%.